Clinical Trial Update: Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients [Phase 1]

View source ↗

Summary

Phase 1/open-label pharmacokinetic study assessing interactions between tazemetostat and CYP enzymes and gastric pH in patients with B-cell lymphoma or advanced…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Mantle Cell Lymphoma
• Marginal Zone Lymphoma
• Mediastinal Lymphoma
• Solid Tumor

Drugs mentioned

• Tazemetostat (tazemetostat)

Snippet

Sponsor: Epizyme, Inc. | Conditions: Diffuse Large B Cell Lymphoma, Primary Mediastinal Lymphoma | Phase 1 | Status: COMPLETED | Results posted: 2021-04-19